You have not yet added any article to your bookmarks!
Join 10k+ people to get notified about new posts, news and tips.
Do not worry we don't spam!
Post by : Badri Ariffin
Pfizer has officially sealed a $10 billion deal to acquire obesity drug developer Metsera, putting an end to a high-stakes bidding war with rival Novo Nordisk that gripped the pharmaceutical industry this past week.
The New York-based pharma giant will pay $86.25 per share in cash, which includes $65.60 upfront and a contingent value right of up to $20.65 per share, depending on future milestones. The offer represents a 3.69% premium over Metsera’s closing price on Friday.
This acquisition marks a major strategic move for Pfizer, which has long sought a foothold in the fast-growing weight-loss drug market — an area dominated by Novo Nordisk and Eli Lilly. Pfizer’s earlier in-house efforts to develop effective obesity treatments had fallen short, making Metsera’s promising drug pipeline an attractive target.
Metsera’s leading experimental drugs — MET-097i, a GLP-1 injectable, and MET-233i, an amylin-mimicking compound — are expected to deliver combined peak sales of around $5 billion, according to analysts. Both drugs target metabolic pathways similar to those powering the success of Wegovy and Mounjaro, the blockbuster drugs from Novo and Lilly.
Novo Nordisk, which had made a last-minute counteroffer to regain ground in the obesity segment it once led, has now been edged out. Metsera’s board stated that Novo’s bid carried “unacceptably high legal and regulatory risks,” favoring Pfizer’s more straightforward cash offer.
The acquisition escalated dramatically from Pfizer’s initial $7.3 billion offer in September, reflecting how competition for promising obesity treatments has intensified. With the deal finalized, Pfizer is betting big on Metsera’s science to help it re-enter one of pharma’s most lucrative markets — one expected to exceed $100 billion globally by the end of the decade.
While Metsera remains unprofitable as its drugs are still in development, Pfizer’s financial muscle and global reach could fast-track their path to approval and commercialization. The agreement now heads to Metsera’s shareholders for approval, setting the stage for one of the most significant biotech acquisitions of the year.
APEC Members Emphasise Safe and Responsible Use of Artificial Intelligence
APEC members discuss responsible AI use, digital innovation and data governance as China and the US
Union of European Clubs Challenge UEFA and EFC Over EU Competition Rules
UEC files an EU competition complaint against UEFA and EFC, challenging club representation, governa
Mohammed Shami Retires From Test Cricket, Eyes White-Ball Career
Mohammed Shami retires from Test cricket after 13 years, with 229 wickets. He will continue playing
Singapore Warns Users About Privacy and Security Risks of AI Agents
Singapore warns users about AI agent security risks, data privacy, online scams and unauthorised acc
Chris Lynn Completes One-Month Ban After Positive Cocaine Test
Australian cricketer Chris Lynn completes a one-month ban after a positive cocaine test during the T
Djokovic Eyes Strong Season Finish as Health Improves Ahead of Paris Masters
Novak Djokovic reports improved health and performance as he targets a strong Paris Masters finish a